FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1855487694> ?p ?o ?g. }

• W1855487694 endingPage "174" @default.
• W1855487694 startingPage "163" @default.
• W1855487694 abstract "OBJECT Large arteriovenous malformations (AVMs) remain difficult to treat, and ideal treatment parameters for volume-staged stereotactic radiosurgery (VS-SRS) are still unknown. The object of this study was to compare VS-SRS treatment outcomes for AVMs larger than 10 ml during 2 eras; Era 1 was 1992-March 2004, and Era 2 was May 2004–2008. In Era 2 the authors prospectively decreased the AVM treatment volume, increased the radiation dose per stage, and shortened the interval between stages. METHODS All cases of VS-SRS treatment for AVM performed at a single institution were retrospectively reviewed. RESULTS Of 69 patients intended for VS-SRS, 63 completed all stages. The median patient age at the first stage of VS-SRS was 34 years (range 9–68 years). The median modified radiosurgery-based AVM score (mRBAS), total AVM volume, and volume per stage in Era 1 versus Era 2 were 3.6 versus 2.7, 27.3 ml versus 18.9 ml, and 15.0 ml versus 6.8 ml, respectively. The median radiation dose per stage was 15.5 Gy in Era 1 and 17.0 Gy in Era 2, and the median clinical follow-up period in living patients was 8.6 years in Era 1 and 4.8 years in Era 2. All outcomes were measured from the first stage of VS-SRS. Near or complete obliteration was more common in Era 2 (log-rank test, p = 0.0003), with 3- and 5-year probabilities of 5% and 21%, respectively, in Era 1 compared with 24% and 68% in Era 2. Radiosurgical dose, AVM volume per stage, total AVM volume, era, compact nidus, Spetzler-Martin grade, and mRBAS were significantly associated with near or complete obliteration on univariate analysis. Dose was a strong predictor of response (Cox proportional hazards, p < 0.001, HR 6.99), with 3- and 5-year probabilities of near or complete obliteration of 5% and 16%, respectively, at a dose < 17 Gy versus 23% and 74% at a dose ≥ 17 Gy. Dose per stage, compact nidus, and total AVM volume remained significant predictors of near or complete obliteration on multivariate analysis. Seventeen patients (25%) had salvage surgery, SRS, and/or embolization. Allowing for salvage therapy, the probability of cure was more common in Era 2 (log-rank test, p = 0.0007) with 5-year probabilities of 0% in Era 1 versus 41% in Era 2. The strong trend toward improved cure in Era 2 persisted on multivariate analysis even when considering mRBAS (Cox proportional hazards, p = 0.055, HR 4.01, 95% CI 0.97–16.59). The complication rate was 29% in Era 1 compared with 13% in Era 2 (Cox proportional hazards, not significant). CONCLUSIONS VS-SRS is an option to obliterate or downsize large AVMs. Decreasing the AVM treatment volume per stage to ≤ 8 ml with this technique allowed a higher dose per fraction and decreased time to response, as well as improved rates of near obliteration and cure without increasing complications. Reducing the volume of these very large lesions can facilitate a surgical approach for cure." @default.
• W1855487694 created "2016-06-24" @default.
• W1855487694 creator A5023667368 @default.
• W1855487694 creator A5033073004 @default.
• W1855487694 creator A5039465135 @default.
• W1855487694 creator A5041760616 @default.
• W1855487694 creator A5043755452 @default.
• W1855487694 creator A5085910888 @default.
• W1855487694 creator A5088040279 @default.
• W1855487694 creator A5088522170 @default.
• W1855487694 creator A5089312606 @default.
• W1855487694 creator A5090403719 @default.
• W1855487694 date "2016-01-01" @default.
• W1855487694 modified "2023-10-18" @default.
• W1855487694 title "Volume-staged radiosurgery for large arteriovenous malformations: an evolving paradigm" @default.
• W1855487694 cites W1482333429 @default.
• W1855487694 cites W1508590061 @default.
• W1855487694 cites W1516319589 @default.
• W1855487694 cites W1527957196 @default.
• W1855487694 cites W1533235876 @default.
• W1855487694 cites W1546743191 @default.
• W1855487694 cites W1565468742 @default.
• W1855487694 cites W1570208766 @default.
• W1855487694 cites W1604299163 @default.
• W1855487694 cites W1622706284 @default.
• W1855487694 cites W1883357276 @default.
• W1855487694 cites W1963567408 @default.
• W1855487694 cites W1973470461 @default.
• W1855487694 cites W1981053175 @default.
• W1855487694 cites W1988036195 @default.
• W1855487694 cites W1990444901 @default.
• W1855487694 cites W2005131595 @default.
• W1855487694 cites W2007302470 @default.
• W1855487694 cites W2009217240 @default.
• W1855487694 cites W2013348842 @default.
• W1855487694 cites W2015345161 @default.
• W1855487694 cites W2017142224 @default.
• W1855487694 cites W2026673146 @default.
• W1855487694 cites W2029901523 @default.
• W1855487694 cites W2034028097 @default.
• W1855487694 cites W2034979257 @default.
• W1855487694 cites W2035742925 @default.
• W1855487694 cites W2041697122 @default.
• W1855487694 cites W2054474589 @default.
• W1855487694 cites W2061894482 @default.
• W1855487694 cites W2070507686 @default.
• W1855487694 cites W2072636222 @default.
• W1855487694 cites W2075581846 @default.
• W1855487694 cites W2083549164 @default.
• W1855487694 cites W2102918890 @default.
• W1855487694 cites W2103728369 @default.
• W1855487694 cites W2145196535 @default.
• W1855487694 cites W2166299500 @default.
• W1855487694 cites W2356936387 @default.
• W1855487694 cites W4235720348 @default.
• W1855487694 doi "https://doi.org/10.3171/2014.12.jns141308" @default.
• W1855487694 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26140495" @default.
• W1855487694 hasPublicationYear "2016" @default.
• W1855487694 type Work @default.
• W1855487694 sameAs 1855487694 @default.
• W1855487694 citedByCount "46" @default.
• W1855487694 countsByYear W18554876942016 @default.
• W1855487694 countsByYear W18554876942017 @default.
• W1855487694 countsByYear W18554876942018 @default.
• W1855487694 countsByYear W18554876942019 @default.
• W1855487694 countsByYear W18554876942020 @default.
• W1855487694 countsByYear W18554876942021 @default.
• W1855487694 countsByYear W18554876942022 @default.
• W1855487694 countsByYear W18554876942023 @default.
• W1855487694 crossrefType "journal-article" @default.
• W1855487694 hasAuthorship W1855487694A5023667368 @default.
• W1855487694 hasAuthorship W1855487694A5033073004 @default.
• W1855487694 hasAuthorship W1855487694A5039465135 @default.
• W1855487694 hasAuthorship W1855487694A5041760616 @default.
• W1855487694 hasAuthorship W1855487694A5043755452 @default.
• W1855487694 hasAuthorship W1855487694A5085910888 @default.
• W1855487694 hasAuthorship W1855487694A5088040279 @default.
• W1855487694 hasAuthorship W1855487694A5088522170 @default.
• W1855487694 hasAuthorship W1855487694A5089312606 @default.
• W1855487694 hasAuthorship W1855487694A5090403719 @default.
• W1855487694 hasBestOaLocation W18554876941 @default.
• W1855487694 hasConcept C126322002 @default.
• W1855487694 hasConcept C126838900 @default.
• W1855487694 hasConcept C141071460 @default.
• W1855487694 hasConcept C146357865 @default.
• W1855487694 hasConcept C151730666 @default.
• W1855487694 hasConcept C2779603958 @default.
• W1855487694 hasConcept C2780387249 @default.
• W1855487694 hasConcept C2989005 @default.
• W1855487694 hasConcept C44249647 @default.
• W1855487694 hasConcept C509974204 @default.
• W1855487694 hasConcept C71924100 @default.
• W1855487694 hasConcept C86803240 @default.
• W1855487694 hasConceptScore W1855487694C126322002 @default.
• W1855487694 hasConceptScore W1855487694C126838900 @default.
• W1855487694 hasConceptScore W1855487694C141071460 @default.
• W1855487694 hasConceptScore W1855487694C146357865 @default.
• W1855487694 hasConceptScore W1855487694C151730666 @default.

• next